Tango 243 polypeptides and uses thereof

Details Tango 243 polypeptides and uses thereof Tango 243 polypeptides and uses thereof

2006-08-01

2006-08-01

O'Hara, Eileen B. (Department: 1646)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C530S350000, C536S023200, C536S023400

Reexamination Certificate

active

07083793

ABSTRACT:
The invention provides isolated nucleic acid molecules, designated TANGO 228 nucleic acid molecules, which encode secreted proteins with homology to the rat MCA-32 protein, isolated nucleic acid molecules, designated TANGO 240 nucleic acid molecules, which encode secreted proteins with homology to theMycobacterium tuberculosishypothetical protein Rv0712, and isolated nucleic acid molecules, designated TANGO 243 nucleic acid molecules, which encode proteins with homology to human PLAP (phospholipase A2-activating protein). The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also described/disclosed.

REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 2003/0166548 (2003-09-01), Peterson et al.
patent: WO 91/10683 (1991-07-01), None
patent: WO 94/01548 (1994-01-01), None
patent: WO 98/56400 (1998-12-01), None
patent: WO 99/33982 (1999-07-01), None
Wang et al., Database GenEmbl, Accession No. U17901, Oct. 22, 1995.
Janknecht et al., PNAS (USA), Viol. 88, pp. 8972-8976, Oct. 1991.
Vukicevic et al., 1996, PNAS USA 93:9021-9026.
U.S. Appl. No. 60/049,316.
Cross et al., “Purification of CpG islands using a methylated DNA binding column” Nature Genetics 6:236-244, Mar. 1994.
MacDonald et al., Accession No. Z62057, Oct. 1995.
Birren et al., Accession No. AC009994, Dec. 7, 1999.
Chopra et al., Accession No. AF083395, Mar., 4, 1999.
Cole et al., Accession No. Z84395, Jun. 17, 1998.
Pirozzi et al., Accession No. U39546, Dec. 28, 1995.
Peterson, J. W., et al., “Cholera Toxin Induces Synthesis of Phospholipase A2-Activating Protein,”Infect. Immun., 64(6):2137-2143 (1996).
Chopra, A. K., et al., “Molecular Characterization of cDNA for Phospholipase A2-Activating Protein,”Biochim. Biophys. Acta, 1444:125-130 (1999).
Bomalaski, J. S., et al., “Phospholipase A2-Activating Protein Induces the Synthesis of IL-1 and TNF in Human Monocytes,”J. Immunol., 154(8):4027-4031 (1995).
Wang, H., et al., “Cloning of a Rat cDNA Encoding a Protein with High Homology to Mouse Phospholipase A2-Activating Protein,”Gene, 161:237-241 (1995).

Affiliated with

Also associated with

Rating

Tango 243 polypeptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tango 243 polypeptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tango 243 polypeptides and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3717093